ACID REDUCER TABLET

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

RANITIDINE (RANITIDINE HYDROCHLORIDE)

Fáanlegur frá:

APOTEX INC

ATC númer:

A02BA02

INN (Alþjóðlegt nafn):

RANITIDINE

Skammtar:

75MG

Lyfjaform:

TABLET

Samsetning:

RANITIDINE (RANITIDINE HYDROCHLORIDE) 75MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

10

Gerð lyfseðils:

OTC

Lækningarsvæði:

HISTAMINE H2-ANTAGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0115150003; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2013-10-24

Vara einkenni

Page
1
of
33
PRODUCT MONOGRAPH
ACID REDUCER
Ranitidine Tablets USP
75 mg and 150 mg Ranitidine (as Ranitidine Hydrochloride)
Histamine H
2
-receptor antagonist
APOTEX INC.,
Date of Revision:
150 Signet Drive
January 24, 2020
Toronto, Ontario
M9L 1T9
Submission Control No.: 238800
Page
2
of
33
TABLE OF CONTENTS
_ _
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
3
WARNINGS AND PRECAUTIONS
.....................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
5
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
...................................................................................
9
OVERDOSAGE
....................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 10
STORAGE AND STABILITY
..............................................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 15
PART II: SCIENTIFIC INFORMATION
..................................................................................
17
PHARMACEUTICAL INFORMATION
.............................................................................
17
DETAILED PHARMACOLOGY
.........................................................................................
18
TOXICOLOGY
.............